Remote digital tracking of early memory and thinking changes
Studies remote digital tests in adults over 45 with possible early Alzheimer's changes.
Plain-language title generated from the registry record
Registry title: Digitally-enhanced, Decentralized, Multi-omics Observational Cohort
Key facts
- Where
- Barcelona, SpainSee the site
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for people over 45 who are seen at a memory clinic or in an observational study, and have early Alzheimer's disease or early Parkinson's disease, plus healthy volunteers. A caregiver or family member must also take part.
- Age
- Over 45 years. For prodromal Parkinson's disease: 60 years or older (30 years or older for people with certain gene changes such as SNCA, Parkin or Pink1).
- Sex
- Men and women can join.
- Disease stage
- Early (preclinical) Alzheimer's disease with MMSE of 27 or more and CDR=0. Or mild cognitive impairment due to Alzheimer's disease with MMSE over 23 and CDR=0.5. Or prodromal Parkinson's disease. Healthy volunteers need MMSE over 27 and CDR=0.
- Earlier treatment
- People taking alpha methyldopa, methylphenidate, amphetamine derivatives or modafinil must be willing and medically able to stop them for at least 5 half-lives before DaTscan imaging. Dopamine receptor blockers, metoclopramide and reserpine cannot be taken within 6 months of screening.
- Biomarker or test result
- Alzheimer's cohort: signs of amyloid-beta build-up in spinal fluid (CSF) or on a PET scan. Healthy volunteers: no signs of amyloid-beta build-up.
Main reasons for not taking part
- Another brain or mental illness that may affect daily life, thinking or social contact
- Clinical diagnosis of Parkinson's disease, other parkinsonism or dementia
- Treatment with blood thinners such as coumadin or heparin
- Abnormal vitamin B12 value, or TSH above the normal range
- No smartphone, or no caregiver or family member who can take part
Read by machine on 9 November 2026.
Where in Spain
- Hospital Clinic BarcelonaBarcelona, SpainNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Greece 2021 Committee
- Trial code
- NCT04701177
- Record updated
- 10 September 2026
- Original description
The study is carried out as part of the GR2021 Priority project "Healthy Brains for life (Age 20-99): Digitally-enhanced personalized medicine study ANANEOS" and code numbered GR-00546 and it will look at the decentralized and remote assessment of the symptoms of preclinical stages in Alzheimer's disease and movement disorders, e.g. Parkinson's. For this study we are looking for participants aged over 45 without cognitive complaints or with subjective perception of cognitive decline or with mild cognitive complaints. Specific aims for the proposed study: a) to develop novel sensitive measures that can provide an early identification of those SCD and MCI individuals harboring AD pathology that are at high risk of cognitive worsening over time; b) to track pre-motor stages in Parkinson's disease and trials that enable active digital functional biomarkers; c) to track disease progression during pre-dementia and pre-motor stages in clinical practice and trials with measures that enable to capture subtle changes.Read full original descriptionShow less
Precision Medicine Initiative Against Alzheimer's Disease (PMIAAD): Digitally-enhanced, Decentralized, Multi-omics, Observational Cohort
The study is carried out as part of the GR2021 Priority project "Healthy Brains for life (Age 20-99): Digitally-enhanced personalized medicine study ANANEOS" and code numbered GR-00546 and it will look at the decentralized and remote assessment of the symptoms of preclinical stages in Alzheimer's disease and movement disorders, e.g. Parkinson's. For this study we are looking for participants aged over 45 without cognitive complaints or with subjective perception of cognitive decline or with mild cognitive complaints. Specific aims for the proposed study: a) to develop novel sensitive measures that can provide an early identification of those SCD and MCI individuals harboring AD pathology that are at high risk of cognitive worsening over time; b) to track pre-motor stages in Parkinson's disease and trials that enable active digital functional biomarkers; c) to track disease progression during pre-dementia and pre-motor stages in clinical practice and trials with measures that enable to capture subtle changes.
Inclusion: Male or female over 45 years of age; Subject is seen at a memory clinic or is part of an observational study; An informant (caregiver/family member) is available to collaborate; Diagnosis of individuals in the AD biological continuum with evidence of amyloid-beta accumulation based on the presence of Aβ load AD biomarkers (either in CSF or PET scan), MMSE, CDR score and cognitive tests as defined by the Guidance document of EMA (2016) or FDA (2018):; preclinical AD: MMSE≥27 and CDR=0, either none or borderline cognitive deficits (compatible with FDA stages 1 and 2, with positive AD biomarkers). Patients reporting subjective cognitive decline who meet the criteria above are eligible for assignment to the preclinical AD group; prodromal AD/MCI due to AD: MMSE >23, CDR=0.5, impairment on cognitive testing with RBANS (compatible with stage 3 FDA, with positive AD biomarkers); Prodromal PD: Male or female age 60 years or older (except age 30 years or older for SNCA, or rate genetic mutations (such as Parkin or Pink1) participants); Individuals taking any of the following drugs: alpha methyldopa, methylphenidate, amphetamine derivatives or modafinil, must be willing and medically able to hold the medication for at least 5 half-lives before DaTscan imaging; Informed consent signed by the subject and informant; Informant should be able to read and communicate in the language of the recruitment centre and available to actively engage in tests and questionnaires; Subject and the informant own a smartphone; Male or female over 45 years of age; Individuals with no evidence of amyloid-beta accumulation based on the presence of Aβ load AD biomarkers (either in CSF or PET scan); Approximately age and gender matched to AD subjects on a group level; An informant is available to collaborate; MMSE >27, CDR=0; In otherwise good health conditions, or with diagnosis mild chronic disorders (of metabolic, respiratory, immunological, cardiologic, and metabolic origin) or any other affections that are controlled by the therapy and do not importantly limit ADLs or social interactions; Able to read and to communicate in the language of the recruitment centre; nformed consent signed by the subject and caregiver; Subject and informant own a smartphone.
Exclusion: Received any of the following drugs: dopamine receptor blockers (neuroleptics), metoclopramide and reserpine within 6 months of Screening visit; Current treatment with anticoagulants (e.g. coumadin, heparin) that might preclude safe completion of the lumbar puncture; Presence of an additional neurological or psychiatric disease that may affect ADL, cognitive function or social interactions; Clinical diagnosis of PD, other parkinsonism, or dementia; Any other kind of disorders that relevantly affect mobility and/or ADL, cognitive function or social interactions (e.g., immune-mediated inflammatory disorders, recovery from recent trauma, stroke, etc.); Presence of an additional neurological or psychiatric disease that may affect ADL, cognitive function or social interactions; Diagnosis of any disorders or post traumatic conditions that are not fully controlled by the therapy and produce relevant limitations of ADL, cognitive function or social interactions; Abnormal VB12 value; TSH above normal range; T3 or T4 outside normal range with clinically significant.